We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia
News

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia
News

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

Credit: Christaras A, CC BY 2.5
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

On July 12, the Food and Drug Administration (FDA) changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia (ALL) to a full approval and expanded the approved indications for its use.


A type of immunotherapy known as a bispecific monoclonal antibody, blinatumomab received accelerated approval in December 2014 for children and adults with B-cell ALL that had returned after earlier treatments (relapsed) or failed to respond to standard therapies at all (refractory). The approval covered only patients whose tumor cells did not have a genetic alteration known as the Philadelphia chromosome.


Under the change to a full approval, however, FDA expanded the indication for blinatumomab to include patients with Philadelphia chromosome–positive ALL.


Accelerated approvals are based on clinical trial results that strongly suggest a therapy provides a real clinical benefit for patients in cases where there is a clinical need. The initial accelerated approval was based on findings from a single-arm phase II trial in which nearly one-third of patients experienced a complete remission.


The change to a regular approval for blinatumomab was based on results from a randomized phase III clinical trial called TOWER that was funded by the drug’s manufacturer, Amgen. In the phase III trial, the median overall survival of patients treated with blinatumomab was nearly twice as long as that of patients treated with chemotherapy regimens that are commonly used in patients with relapsed or refractory B-cell ALL.


A March 2017 Cancer Currents post described details of the trial and its potential impact on patient care and future research involving blinatumomab.


Expanding the approved indication for blinatumomab to include people with Philadelphia chromosome–positive disease was based on results from a single-arm study, also funded by Amgen, in which more than one-third of patients achieved a complete remission.


This article has been republished from materials provided by NIH. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement